Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market for Active Pharmaceutical Ingredients (APIs) catering to cancer treatment is a vital segment within the pharmaceutical industry. APIs serve as the core components of various cancer medications, playing a crucial role in their efficacy.
Increasing Prevalence of Cancer: One of the primary market factors driving the demand for APIs in cancer treatment is the escalating prevalence of cancer worldwide. With cancer cases on the rise across the globe, the need for effective APIs to develop innovative therapies is ever-growing.
Technological Advancements: The continuous advancements in technology have revolutionized cancer treatment, leading to the development of novel APIs with enhanced therapeutic properties. Innovations such as targeted therapies and immunotherapies rely heavily on sophisticated APIs, fueling market growth.
Rising Healthcare Expenditure: The increasing healthcare expenditure, particularly in developed regions, contributes significantly to the growth of the API market for cancer treatment. As governments and private sectors allocate more resources to combat cancer, the demand for high-quality APIs surges.
Regulatory Environment: Stringent regulatory standards imposed by regulatory bodies like the FDA (Food and Drug Administration) and EMA (European Medicines Agency) significantly impact the API market for cancer treatment. Compliance with rigorous regulatory requirements is essential for API manufacturers, influencing market dynamics.
Growing Focus on Personalized Medicine: The shift towards personalized medicine tailored to individual patient profiles drives the demand for APIs that can target specific molecular pathways involved in cancer progression. This personalized approach fosters the development of niche APIs and fosters market expansion.
Competition Among API Manufacturers: Intense competition among API manufacturers, both domestic and international, shapes the market landscape. Companies strive to differentiate their products by focusing on factors such as quality, cost-effectiveness, and innovation to gain a competitive edge in the market.
Increasing Research and Development Activities: Robust research and development (R&D) initiatives aimed at discovering novel APIs for cancer treatment propel market growth. Pharmaceutical companies and academic institutions invest substantially in R&D to identify promising compounds with therapeutic potential, driving innovation in the API market.
Globalization of Pharmaceutical Supply Chains: The globalization of pharmaceutical supply chains has a profound impact on the API market for cancer treatment. The outsourcing of API manufacturing to countries with lower production costs, coupled with stringent quality standards, influences market dynamics and pricing strategies.
Emerging Markets: Emerging markets, particularly in Asia-Pacific and Latin America, present lucrative opportunities for API manufacturers due to factors such as a large patient population, increasing healthcare infrastructure, and favorable regulatory policies. These regions are witnessing rapid growth in demand for APIs for cancer treatment.
Patent Expirations and Generic Competition: Patent expirations of branded cancer drugs pave the way for the entry of generic versions, intensifying competition among API manufacturers. Generic APIs offer cost-effective alternatives, driving market growth and accessibility of cancer treatment options.
Shift Towards Biologics and Biosimilars: The growing preference for biologics and biosimilars in cancer treatment influences the API market dynamics. Biologic APIs, derived from living organisms, and biosimilars, which are highly similar to existing biologics, are gaining traction, reshaping the competitive landscape.
Impact of COVID-19 Pandemic: The COVID-19 pandemic has had a multifaceted impact on the API market for cancer treatment. While disruptions in supply chains initially posed challenges, increased focus on healthcare infrastructure and drug development in response to the pandemic has stimulated market growth.
Patient Access and Affordability: Ensuring patient access to affordable cancer treatment remains a critical concern, driving efforts to optimize API production processes and reduce manufacturing costs. Affordable APIs are essential to expanding access to life-saving cancer therapies globally.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|
Active Pharmaceutical Ingredient for Cancer Market Highlights:
Active Pharmaceutical Ingredient for Cancer Market Synopsis
The Active Pharmaceutical Ingredient (API) for Cancer market is projected to reach USD 250191.59 Million by 2030 at 7.40% CAGR during the forecast period 2022-2030 API for cancer market, including conventional syringes, needle-free injectors, and auto and pen injectors have been extensively utilized for the administration of drugs to treat medical conditions ranging from cancer to autoimmune disorders. The market for API for cancer has witnessed continuously rising R&D. As a result, the active pharmaceutical ingredient for cancer market is fragmented into various advanced products as per the molecules. Following the illustrated course, it is projected that increasing prevalence of cancer, growing technologies for treatments of various types of cancer, and rising FDA approvals of anticancer drugs drives the market growth. However, side effects associated with the medication are estimated to restrain the market growth during the forecast period.
Active Pharmaceutical Ingredient for Cancer Market Dynamics
The active pharmaceutical ingredient for cancer market is driven by increasing prevalence of cancer drives the market growth. According to the statistical report published by the World Health Organization (WHO) in 2018, around 18.1 million new cases of cancers were estimated reported worldwide. This indicates a potential for growth in the global API for cancer market.
The other factors that are driving the global API for cancer market are growing technologies for treatments of various types of cancer, and rising FDA approvals of anticancer drugs, growing demand for newly developed small molecules drugs, and others.
Global Active Pharmaceutical Ingredient for Cancer Market Size, by Indication, 2018 & 2025 (USD Million) Â 
Source: MRFR Analysis
Active Pharmaceutical Ingredient for Cancer Market Segmentation
The global API for cancer market has been segmented into by type, indications, and end users.
Based on type it is segmented into tinib, parib, rafenib, lisib, degib, ciclib, and others
Based on indication, it is segmented into blood cancer, skin cancer, lungs cancer, breasts cancer, pancreas cancer, others.
Based on end user, the market is segmented into pharmaceutical companies, research organizations, others.
Active Pharmaceutical Ingredient for Cancer Market Key Players
The prominent players in the global API for cancer market are AbbVie, Pfizer Inc, Boehringer Ingelheim International GmbH, AstraZeneca, Novartis AG., F. Hoffmann-La Roche AG, Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd, Johnson & Johnson, Merck & Co. Inc., Amgen Inc., and others.
Global Active Pharmaceutical Ingredient for Cancer Market Share, by Region, 2018 (%) Â 
Source: MRFR Analysis
Active Pharmaceutical Ingredient for Cancer Market Regional Analysis
The global API for cancer market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is anticipated to dominate the global API for cancer market owing to the rising awareness about the condition and high healthcare expenditure. The Americas is expected to reach USD 34,300.00 million by 2025 at a CAGR of 8.1% from 2018 to 2025. The Americas region accounted largest regional market owing to the growing biotechnology industry, the growing prevalence of cancer, and a highly developed healthcare sector. Â
Europe accounted for the second-largest market share in 2018 due to extensive R&D for healthcare, increasing funding, and growing adoption of the technology within the region.
On the other hand, the Middle East and Africa is expected to observe slow growth due to less exposure to healthcare services, lack of awareness, and stringent government rules and regulations.
Key Updates
- In May 2019, Eli Lilly and Company received US Food and Drug Administration approval for its drug Cyramza (ramucirumab) a human VEGFR2 antagonist. It is a recombinant molecule of the human IgG1 monoclonal antibody.
- In April 2019 Johnson & Johnson received US Food and Drug Administration approval for product Balversa (erdafitinib), oral fibroblast growth factor receptor (FGFR) kinase inhibitor.
Market Segmentation
Global Active Pharmaceutical Ingredient for Cancer Market, by Type
- Tyrosine Kinase Inhibitor (Tinib)
- Ponatinib
- Brigatinib
- Ruxolitinib
- Erlotinib
- Alectinib
- Cobimetinib
- Neratinib
- Osimertinib
- Acalabrutinib
- Bosutinib
- Crizotinib
- Axitinib
- Sunitinib
- Ceritinib
- Imatinib
- Lapatinib
- Afatinib
- Cabozantinib
- Dasatinib
- Ibrutinib
- Lenvatinib
- Gefitinib
- Others
- Proteasome Inhibitors (Parib)
- Olaparib
- Rucaparib
- Niraparib
- BRAF Kinase Inhibitors (rafenib)
- Sorafenib
- Regorafenib
- Vemurafenib
- Dabrafenib
- Enasidenib
- Others
- Phosphatidylinositol 3-Kinase Inhibitors (Lisib)
- Idelalisib
- Copanlisib
- SMO Receptor Antagonists (Degib)
- Sonidegib
- Vismodegib
- Cyclin Dependent Kinase Inhibitors (Ciclib)
- Palbociclib
- Ribociclib
- Abemaciclib
- Others
Global API for Cancer Market, by Indication
- Blood Cancer
- Skin Cancer
- Lungs Cancer
- Breasts Cancer
- Pancreas Cancer
- Others
Global Active Pharmaceutical Ingredient for Cancer Market, by End User
- Pharmaceutical Companies
- Research Organizations
- Others
Global Active Pharmaceutical Ingredient for Cancer Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Available Additional Customizations
- Additional Companies
- Supply & Demand Analysis
Intended Audience
- Pharmaceutical Companies
- Hospitals and Clinics
- Regulatory Agencies
- Research Institutes
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
